BP11150 L-PLCL 75:25, Lauryl Ester Terminated, IV: 1.0–2.0 dl/g

L-PLCL 75:25, Lauryl Ester Terminated, IV: 1.0–2.0 dl/g Description

L-PLCL 75:25, Lauryl Ester Terminated, IV: 1.0–2.0 dl/g is a copolymer composed of poly(L-lactide-co-ε-caprolactone) with lauryl ester end groups. The intrinsic viscosity specification provides insights into its molecular weight distribution, significantly influencing melt processing and biodegradability. This formulation meets rigorous standards for biocompatibility, making it suitable for transient biomedical devices and tissue engineering scaffolds. Its powder form facilitates various processing methods and ensures batch uniformity.

L-PLCL 75:25, Lauryl Ester Terminated, IV: 1.0–2.0 dl/g Applications

Healthcare Applications
- Used as a biodegradable scaffold in tissue regeneration to achieve improved cellular integration by leveraging its controlled degradation profile.
- Applied as an implant coating in temporary devices to mitigate inflammatory responses by utilising its biocompatible surface properties.

Industrial Applications
- Applied as a component in resorbable sutures to achieve gradual load transfer by leveraging its predictable degradation kinetics.

L-PLCL 75:25, Lauryl Ester Terminated, IV: 1.0–2.0 dl/g Packing

The polymer is packaged in moisture-resistant, anti-static sealed bags that are enclosed in rigid, thermo-stabilised containers. This packaging method protects against contamination and environmental exposure. Each package carries clear labeling and batch codes, ensuring traceability during storage and transport. Custom container sizes and configurations are available upon request to address specific storage requirements.

Additional Information

We professionally provide custom synthesis services for poly(ε-caprolactone) (PCL)-based binary copolymers, precisely meeting the differentiated requirements of biomaterial R&D and high-end medical device applications for polymer performance.

Key customisable copolymer systems include:

PCL-Polylactide Copolymers [P(CL-LA)]
Copolymers can be synthesised using L-lactide (PLLA), D-lactide (PDLA), or racemic lactide (PDLLA) segments, effectively improving the brittleness of PLA, enhancing material toughness and ductility, and enabling flexible adjustment of degradation profiles from several months to years.

PCL-Poly(lactide-co-glycolide) Copolymers [P(CL-LGA)]
Copolymers can be tailored with various PLGA ratios (e.g., 75/25, 50/50, 85/15), significantly improving fracture toughness. By adjusting PCL content and sequence structure, the in-vivo degradation kinetics and mechanical property decay can be precisely controlled, making these materials ideal for drug delivery systems and soft tissue repair scaffolds.

PCL-Poly(trimethylene carbonate) Copolymers [P(CL-TMC)]
Combining the hydrophobic semi-crystallinity of PCL with the high elasticity of PTMC yields elastomeric materials with excellent flexibility, low modulus, and controllable degradation. Suitable for interventional devices requiring high compliance, such as vascular stents and nerve conduits.

Core Dimensions of Customisation:

Flexible Inherent Viscosity Selection
We offer products with inherent viscosity ranging from 0.5–4.0 dL/g (expandable upon request), suitable for various processing techniques such as electrospinning, solution coating, melt extrusion, and injection moulding.

Tailorable End-Group Functionality
Custom end-group structures are supported, including hydroxyl (-OH), carboxyl (-COOH), ester groups (e.g., -COOCH₃), as well as click-chemistry functional groups such as azide or alkyne. These provide convenient chemical handles for subsequent molecular grafting, surface modification, or cross-linked network formation.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.